Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls

Abstract

Loss of HER2 in previously HER2-positive breast tumors is not rare, occurring in up to 50% of breast cancers; however, clinical research and practice underestimate this issue. Many studies have reported the loss of HER2 after neoadjuvant therapy and at metastatic relapse and identified clinicopathological variables more frequently associated with this event. Nevertheless, the biological mechanisms underlying HER2 loss are still poorly understood. HER2 downregulation, intratumoral heterogeneity, clonal selection, and true subtype switch have been suggested as potential causes of HER2 loss, but translational studies specifically investigating the biology behind HER2 loss are virtually absent. On the other side, technical pitfalls may justify HER2 loss in some of these samples. The best treatment strategy for patients with HER2 loss is currently unknown. Considering the prevalence of this phenomenon and its apparent correlation with worse outcomes, we believe that correlative studies specifically addressing HER2 loss are warranted.

Keywords

HER2 loss / breast cancer / subtype switch / tumor heterogeneity / clonal selection / HER2 downregulation / technical pitfalls

References

[1] Marchiò C,Marques A,Berrino E.Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond.Semin Cancer Biol2021;72:123-35

[2] Tolaney SM,Dang CT.Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.N Engl J Med2015;372:134-41 PMCID:PMC4313867

[3] Minckwitz G, Huang CS, Mano MS, et al; KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer.N Engl J Med2019;380:617-28

[4] Cortés J,Chung WP.DESTINY-Breast03 Trial InvestigatorsTrastuzumab deruxtecan versus trastuzumab emtansine for breast cancer.N Engl J Med2022;386:1143-54

[5] Swain SM,Kim S.Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.Lancet Oncol2020;21:519-30

[6] Slamon DJ,Wong SG,Ullrich A.Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science1987;235:177-82

[7] Slamon DJ,Jones LA.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.Science1989;244:707-12

[8] Wolff AC,Allison KH.Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline Focused update.J Clin Oncol2018;36:2105-22

[9] Niikura N,Hayashi N.Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.J Clin Oncol2012;30:593-9 PMCID:PMC3295557

[10] Schrijver WAME,van Gils CH,Moelans CB.Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis.J Natl Cancer Inst2018;110:568-80

[11] Branco FP,Silva FF.Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer.Am J Transl Res2019;11:6110-6 PMCID:PMC6789273

[12] Amir E,Geddie W.Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer.J Clin Oncol2012;30:587-92 PMCID:PMC5015424

[13] Mathews JC,Levine AJ,Deasy JO.Robust and interpretable PAM50 reclassification exhibits survival advantage for myoepithelial and immune phenotypes.NPJ Breast Cancer2019;5:30 PMCID:PMC6733897

[14] Baselga J.Mechanism of action of anti-HER2 monoclonal antibodies.Ann Oncol2001;12 Suppl 1:S35-41

[15] Venter D,Tuzi N.Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification.Lancet1987;330:69-72

[16] Yarden Y.Untangling the ErbB signalling network.Nat Rev Mol Cell Biol2001;2:127-37

[17] Scaltriti M,Guzman M.Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.Oncogene2009;28:803-14

[18] Shi Y,Meng W,Zhang N.Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation.Breast Cancer Res2014;16:R33 PMCID:PMC4053225

[19] Kominsky SL,Lake FA,Johnson HM.Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells.Cancer Res2000;60:3904-8.

[20] Bon G,Laquintana V.Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.J Exp Clin Cancer Res2020;39:279 PMCID:PMC7731769

[21] Li G,Shen BQ.Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells.Mol Cancer Ther2018;17:1441-53

[22] Hunter FW,Lipert B.Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.Br J Cancer2020;122:603-12 PMCID:PMC7054312

[23] Loganzo F,Sung M.Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments.Mol Cancer Ther2015;14:952-63

[24] Linehan AS,Morris PG.Profile of trastuzumab deruxtecan in the management of patients with HER2-positive unresectable or metastatic breast cancer: an evidence-based review.Breast Cancer2021;13:151-9 PMCID:PMC7920506

[25] Mosele M,Dieras V.LBA1 unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): biomarker analyses from patients from DAISY trial.Ann Oncol2022;33:S123

[26] Guarneri V,Griguolo G.of the CHER-Lob study teamTrastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial.Eur J Cancer2021;153:133-41

[27] trastuzumab, and capecitabine for her2-positive metastatic breast cancer.N Engl J Med2020;382:586

[28] Filho OM,Stein S.Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab.Cancer Discov2021;11:2474-87 PMCID:PMC8598376

[29] Janiszewska M,Metzger Filho O.The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.JCI Insight2021;6:147617 PMCID:PMC8262355

[30] Annaratone L,Wernersson E.Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization.Oncotarget2017;8:18680-98 PMCID:PMC5386639

[31] Vance GH,Bloom KJ.College of American PathologistsGenetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.Arch Pathol Lab Med2009;133:611-2

[32] Wolff AC,Hicks DG.American Society of Clinical Oncology, College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.J Clin Oncol2013;31:3997-4013

[33] Caswell-Jin JL,Reiter JG.Publisher correction: clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.Nat Commun2019;10:2433 PMCID:PMC6542801

[34] Parker JS,Cheang MC.Supervised risk predictor of breast cancer based on intrinsic subtypes.J Clin Oncol2009;27:1160-7 PMCID:PMC2667820

[35] Sørlie T,Tibshirani R.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci USA2001;98:10869-74 PMCID:PMC58566

[36] Prat A,Adamo B.Clinical implications of the intrinsic molecular subtypes of breast cancer.Breast2015;24 Suppl 2:S26-35

[37] Prat A,Adamo B.Intrinsic molecular subtypes of HER2+ breast cancer.Oncotarget2017;8:73362-3 PMCID:PMC5650264

[38] Genome Atlas Network. Comprehensive molecular portraits of human breast tumours.Nature2012;490:61-70 PMCID:PMC3465532

[39] Perou CM,Eisen MB.Molecular portraits of human breast tumours.Nature2000;406:747-52

[40] Carey LA,Cirrincione CT.Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib.J Clin Oncol2016;34:542-9 PMCID:PMC4980567

[41] Brasó-Maristany F,Pascual T.Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.Nat Commun2020;11:385 PMCID:PMC6971277

[42] Bianchini G,Carey L.Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies.Ann Oncol2018;29:viii61

[43] Llombart-cussac A,Paré L.HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.Lancet Oncol2017;18:545-54

[44] Pernas S,Climent F.PAM50 subtypes in baseline and residual tumors following neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer: a consecutive-series from a single institution.Front Oncol2019;9:707 PMCID:PMC6691353

[45] Hanna WM,Bilous M.HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.Mod Pathol2014;27:4-18

[46] Sauter G,Bartlett JM,Press MF.Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.J Clin Oncol2009;27:1323-33

[47] Press MF,Bernstein L.Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.Clin Cancer Res2005;11:6598-607

[48] Wolff AC,Hicks DG.American Society of Clinical Oncology, College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Arch Pathol Lab Med2014;138:241-56

[49] Pusztai L,Kelly CM.Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis.Oncologist2010;15:1164-8 PMCID:PMC3227913

[50] Roche PC,Jenkins RB.Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.J Natl Cancer Inst2002;94:855-7

[51] Reddy JC,Anderson SM.Concordance between central and local laboratory HER2 testing from a community-based clinical study.Clin Breast Cancer2006;7:153-7

[52] Pfitzner BM,Lindner J.Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years.Mod Pathol2018;31:607-15

[53] Perez EA,Davidson NE.HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.J Clin Oncol2006;24:3032-8

[54] Marchiò C,Gugliotta P.Does chromosome 17 centromere copy number predict polysomy in breast cancer?.J Pathol2009;219:16-24

[55] Varga Z,Wang Z.Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer.Breast Cancer Res Treat2012;132:925-35

[56] Warneke VS,Böger C.Her2/neu testing in gastric cancer: evaluating the risk of sampling errors.Ann Oncol2013;24:725-33 PMCID:PMC3574551

[57] Verschoor N,Jager A,Wilting SM.Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review.Cancer Treat Rev2022;106:102384

[58] Dekker TJ,Hooijer GK.Reliability of core needle biopsy for determining ER and HER2 status in breast cancer.Ann Oncol2013;24:931-7

[59] Senkus E,Ohno S.ESMO Guidelines CommitteePrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol2015;26 Suppl 5:v8-30

[60] Wetzel CL,Gardiner S,Johnson N.Loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes.J Surg Oncol2021;124:1224-34

[61] Tapia C,Wagner U.HER2 gene status in primary breast cancers and matched distant metastases.Breast Cancer Res2007;9:R31 PMCID:PMC1929093

[62] Kasami M,Honda M.Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy.Breast2008;17:523-7

[63] Taucher S,Mader RM.Influence of Neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer.Breast Cancer Res Treat2003;82:207-13

[64] Varga Z,Pestalozzi B.Stability of the HER2 gene after primary chemotherapy in advanced breast cancer.Virchows Arch2005;446:136-41

[65] Ignatov T,Eggemann H,Ignatov A.Loss of HER2 after HER2-targeted treatment.Breast Cancer Res Treat2019;175:401-8